Financing

Biomia, the first company spun out from BioInnovation Institute’s Bio Studio programme, has secured $3 million in pre-seed financing from an international syndicate of investors. Biomia says it plans to use the investment to accelerate its development of plant-inspired natural and new-to-nature halogenated small molecule drug candidates and further build its biosynthetic manufacturing platform. Chief […]

AbolerIS Pharma has raised €27.3 million in a Series A financing led by Caixa Capital Risc and co-led by Sound Bioventures and Newton Biocapital. Proceeds from the financing will enable AbolerIS to accelerate the development of its lead programme in clinical trials and explore its effectiveness in additional autoimmune diseases. AbolerIS’ lead programme is a […]

A Series B financing round has raised Genesis Therapeutics’ total capital to over $280 million, which will be used to bring the company’s artificial intelligence (AI)-enabled pipeline into clinical development. Genesis will also invest in continued development of generative and predictive AI methods, which form the foundation of the Genesis Exploration of Molecular Space (GEMS) […]

The second quarter of 2023 has seen steady growth in financing activity for the UK’s life sciences sector, according to new data released by the BioIndustry Association (BIA) and Clarivate. The positive news comes soon after industry figures welcomed recent announcements to unlock new sources of capital in the City of London. Last month, the […]

Immuno-oncology company Crescendo Biologics has revealed plans to augment the ongoing Phase Ib clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort. Additional financing of $32 million has been secured with the support of all major existing shareholders, including Sofinnova Partners, Andera Partners, IP Group BioNTech, Takeda and Quan […]

Camena Bioscience has closed a $10m Series A financing round, which will be used to scale operations and continue development of DNA synthesis platform gSynth. Synthetic genes are widely used by researchers to understand the mechanisms of disease, and in the drug discovery process to combat them. However, the cost, time and accuracy of traditional […]

Iktos has raised €15.5m in a Series A funding round to expand its artificial intelligence-based drug discovery technologies and solutions. The round was co-led by new investors M Ventures and Debiopharm Innovation Fund with participation from Omnes Capital. The financing will enable the company to launch Iktos Robotics; a drug discovery platform which combines artificial […]

Cerevance has expanded its Series B funding round with an additional close of $51 million, bringing the total to $116 million.  The financing will support upcoming clinical trials focused on Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), and schizophrenia.   “We are thrilled to secure additional funding from world-class investors who strongly support the need for novel […]

Evonetix has completed a $24 million financing round, extending its total series B funding to over $54 million.   The fundraise was led by existing investor Foresite Capital, with Molten Ventures, Morningside, DCVC, Cambridge Consultants, Civilization Ventures and Providence also participating in the round.  The investment will enable the continued development of Evonetix’s semiconductor chips to […]

Grey Wolf Therapeutics has closed an oversubscribed $49 million Series B financing co-led by Pfizer Ventures and Earlybird Venture Capital, with investment from Oxford Science Enterprises, British Patient Capital, Canaan and Andera Partners.   Proceeds will support the continued development of the company’s first-of-its-kind immuno-oncology approaches designed to overcome key resistance mechanisms through the creation of […]

Tellus Therapeutics, a company developing treatments for newborns in the neonatal intensive care unit (NICU), announced the closing of a Series A financing round of $35 million led by the Perceptive Xontogeny Venture Fund.   The capital will be used to continue preclinical work conducted through the seed investment with the Xontogeny development team and to […]

Clinical biotechnology company Storm Therapeutics has successfully completed a USD $30 million Series B financing round.  The investment allows the company to focus on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases.  The financing was co-led by existing investors M Ventures, Pfizer Ventures, Taiho Ventures LLC, […]

Neobe Therapeutics, an early-stage startup, has raised £520K ($628,000) in equity funding to engineer live biotherapeutics to remove barriers to immune infiltration in solid tumours.  While immunotherapies have revolutionised the treatment of cancer, the large majority of patients with solid tumours (up to 85%) still do not respond to them. Neobe was founded by Pedro […]

Magnitude Biosciences has closed a fourth round of investment to accelerate the scaling of its business providing C. elegans research services.   A total investment of £500,000 will be made by longstanding investors the North East (ERDF) Innovation Fund Limited Partnership, supported by the European Regional Development Fund and managed by Northstar Ventures, and Saker Capital.   […]

A new biotechnology company plans to pioneer the integrated mapping of disease networks for precision therapeutics. Rezo Therapeutics has launched with $78 million from a Series A financing, led by SR One, a16z Bio + Health, and Norwest Venture Partners. The company’s platform is based on technology from the Quantitative Biosciences Institute (QBI) at the […]